CN111388382A - 一种用于美白亮肤的组合物及其在化妆品中的应用 - Google Patents
一种用于美白亮肤的组合物及其在化妆品中的应用 Download PDFInfo
- Publication number
- CN111388382A CN111388382A CN201910001955.1A CN201910001955A CN111388382A CN 111388382 A CN111388382 A CN 111388382A CN 201910001955 A CN201910001955 A CN 201910001955A CN 111388382 A CN111388382 A CN 111388382A
- Authority
- CN
- China
- Prior art keywords
- whitening
- skin
- composition
- glabridin
- brightening
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000002087 whitening effect Effects 0.000 title claims abstract description 45
- 238000005282 brightening Methods 0.000 title claims abstract description 32
- 239000000203 mixture Substances 0.000 title claims abstract description 30
- 239000002537 cosmetic Substances 0.000 title claims abstract description 26
- LBQIJVLKGVZRIW-ZDUSSCGKSA-N glabridin Chemical compound C1([C@H]2CC3=CC=C4OC(C=CC4=C3OC2)(C)C)=CC=C(O)C=C1O LBQIJVLKGVZRIW-ZDUSSCGKSA-N 0.000 claims abstract description 31
- 229940093767 glabridin Drugs 0.000 claims abstract description 31
- PMPYOYXFIHXBJI-ZDUSSCGKSA-N glabridin Natural products C1([C@H]2CC=3C=CC4=C(C=3OC2)CCC(O4)(C)C)=CC=C(O)C=C1O PMPYOYXFIHXBJI-ZDUSSCGKSA-N 0.000 claims abstract description 31
- LBQIJVLKGVZRIW-UHFFFAOYSA-N glabridine Natural products C1OC2=C3C=CC(C)(C)OC3=CC=C2CC1C1=CC=C(O)C=C1O LBQIJVLKGVZRIW-UHFFFAOYSA-N 0.000 claims abstract description 31
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 claims abstract description 28
- 229940089468 hydroxyethylpiperazine ethane sulfonic acid Drugs 0.000 claims abstract description 28
- 239000002131 composite material Substances 0.000 claims abstract description 9
- 239000002308 endothelin receptor antagonist Substances 0.000 claims abstract description 9
- 239000000686 essence Substances 0.000 claims description 16
- 239000000284 extract Substances 0.000 claims description 13
- 241000196324 Embryophyta Species 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 7
- 241000209490 Nymphaea Species 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 206010040829 Skin discolouration Diseases 0.000 claims description 3
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 claims description 3
- 244000146462 Centella asiatica Species 0.000 claims description 2
- 235000004032 Centella asiatica Nutrition 0.000 claims description 2
- 241001648859 Lilium candidum Species 0.000 claims description 2
- 235000016791 Nymphaea odorata subsp odorata Nutrition 0.000 claims description 2
- 241000736199 Paeonia Species 0.000 claims description 2
- 235000006484 Paeonia officinalis Nutrition 0.000 claims description 2
- 240000005001 Paeonia suffruticosa Species 0.000 claims description 2
- 235000003889 Paeonia suffruticosa Nutrition 0.000 claims description 2
- 108010006161 conchiolin Proteins 0.000 claims description 2
- 239000006071 cream Substances 0.000 claims 1
- 239000006210 lotion Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 210000003491 skin Anatomy 0.000 abstract description 40
- 230000000694 effects Effects 0.000 abstract description 11
- 102000003425 Tyrosinase Human genes 0.000 abstract description 6
- 108060008724 Tyrosinase Proteins 0.000 abstract description 6
- 229920000832 Cutin Polymers 0.000 abstract description 3
- 230000004069 differentiation Effects 0.000 abstract description 2
- 210000002752 melanocyte Anatomy 0.000 abstract description 2
- -1 polyethylene terephthalate Polymers 0.000 abstract 1
- 229920000139 polyethylene terephthalate Polymers 0.000 abstract 1
- 239000005020 polyethylene terephthalate Substances 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 16
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 230000006872 improvement Effects 0.000 description 7
- TXFPEBPIARQUIG-UHFFFAOYSA-N 4'-hydroxyacetophenone Chemical compound CC(=O)C1=CC=C(O)C=C1 TXFPEBPIARQUIG-UHFFFAOYSA-N 0.000 description 6
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 229940015975 1,2-hexanediol Drugs 0.000 description 3
- LXAHHHIGZXPRKQ-UHFFFAOYSA-N 5-fluoro-2-methylpyridine Chemical compound CC1=CC=C(F)C=N1 LXAHHHIGZXPRKQ-UHFFFAOYSA-N 0.000 description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 3
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 3
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 3
- 102000002045 Endothelin Human genes 0.000 description 3
- 108050009340 Endothelin Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 240000005979 Hordeum vulgare Species 0.000 description 3
- 235000007340 Hordeum vulgare Nutrition 0.000 description 3
- 229920002385 Sodium hyaluronate Polymers 0.000 description 3
- 229920002125 Sokalan® Polymers 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 229960000458 allantoin Drugs 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- OWBTYPJTUOEWEK-UHFFFAOYSA-N butane-2,3-diol Chemical compound CC(O)C(C)O OWBTYPJTUOEWEK-UHFFFAOYSA-N 0.000 description 3
- 229960001631 carbomer Drugs 0.000 description 3
- 229940106189 ceramide Drugs 0.000 description 3
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 3
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 229940087068 glyceryl caprylate Drugs 0.000 description 3
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 description 3
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- GHBFNMLVSPCDGN-UHFFFAOYSA-N rac-1-monooctanoylglycerol Chemical compound CCCCCCCC(=O)OCC(O)CO GHBFNMLVSPCDGN-UHFFFAOYSA-N 0.000 description 3
- 229940010747 sodium hyaluronate Drugs 0.000 description 3
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 3
- 239000000516 sunscreening agent Substances 0.000 description 3
- 239000000230 xanthan gum Substances 0.000 description 3
- 229920001285 xanthan gum Polymers 0.000 description 3
- 229940082509 xanthan gum Drugs 0.000 description 3
- 235000010493 xanthan gum Nutrition 0.000 description 3
- 241000282414 Homo sapiens Species 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- 102000011782 Keratins Human genes 0.000 description 2
- 108010076876 Keratins Proteins 0.000 description 2
- 241001598113 Laminaria digitata Species 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000004299 exfoliation Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 2
- 230000003061 melanogenesis Effects 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 230000000475 sunscreen effect Effects 0.000 description 2
- 101710163881 5,6-dihydroxyindole-2-carboxylic acid oxidase Proteins 0.000 description 1
- 102100030310 5,6-dihydroxyindole-2-carboxylic acid oxidase Human genes 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000512259 Ascophyllum nodosum Species 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 239000002211 L-ascorbic acid Substances 0.000 description 1
- 235000000069 L-ascorbic acid Nutrition 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 235000003205 Smilax rotundifolia Nutrition 0.000 description 1
- 240000009022 Smilax rotundifolia Species 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 229960000271 arbutin Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 210000001787 dendrite Anatomy 0.000 description 1
- 239000007854 depigmenting agent Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- VJNCICVKUHKIIV-UHFFFAOYSA-N dopachrome Chemical compound O=C1C(=O)C=C2NC(C(=O)O)CC2=C1 VJNCICVKUHKIIV-UHFFFAOYSA-N 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 1
- 229960004705 kojic acid Drugs 0.000 description 1
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000008099 melanin synthesis Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 125000002801 octanoyl group Chemical group C(CCCCCCC)(=O)* 0.000 description 1
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 230000005808 skin problem Effects 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 1
- 229960000401 tranexamic acid Drugs 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
Abstract
一种用于美白亮肤的组合物及其在化妆品中的应用,组合物包括以下组分:光甘草定载体,羟乙基哌嗪乙烷磺酸(HEPES),内皮素拮抗剂,植物复合精华。该美白亮肤的组合物可以有效抑制酪氨酸酶活性、抑制黑色素细胞分化、清除自由基、软化角质、提高皮肤抵御能力等,光甘草定载体技术与植物鲜活成分共存,配合内皮素拮抗剂的强力美白淡斑功效,在HEPES的存在下,协同增效,达到优异的皮肤美白亮肤的功效。
Description
技术领域
本发明专利涉及化妆品领域,具体涉及一种用于美白亮肤的组合物及其在化妆品中的应用。
背景技术
现代社会,随着人们生活、工作节奏的加快以及各种外在因素,如环境、紫外线等,我们遇到的皮肤问题越来越多,肤色暗沉没有光泽,美白亮肤的成为越来越重要的需求。随着年龄的增长,肤色暗沉黑色素的增加,导致我们,特别是东方黄种人,对于美白的需求更加渴望。所以提亮肤色和美白皮肤的化妆品产品市场越来越火爆,行之有效的美白亮肤的产品配方开发也成为众多化妆品厂家配方工程师的头等大事。
现代皮肤科学研究表明,肤色暗沉没有光泽主要与黑色素的增加密不可分。黑色素的形成机理过程为:黑素细胞内的酪氨酸(在酪氨酸酶的作用下)---多巴(在酪氨酸酶的作用下)---多巴醌---多巴色素(在多巴色素转换酶,DHI氧化酶,DHICA氧化酶的综合作用下)---最终聚合形成真黑色素。在黑色素合成的过程中,酪氨酸酶是第一步的限速酶,也是关键酶。随着真黑色素的形成,人类的肤色发生了变化,这些黑色素细胞树突转移到表皮基底层细胞,随着细胞的新陈代谢而进入角质层,最后随着角质细胞脱落。因此在美白产品配方的设计上,抑制酪氨酸酶的活性并阻断黑色素的合成途径,同时快速温和的剥离角质层的黑色素,就成为非常关键的步骤。
当前,一般的皮肤美白剂主要是通过抑制酪氨酸酶活性或者阻断酪氨酸酶生成黑色素的合成途径,从而减少黑色素的生产达到美白的作用。此类传统皮肤美白剂主要有熊果苷、氢醌及衍生物、L-抗坏血酸及衍生物、曲酸及其衍生物、维生素C及其衍生物、烟酰胺、传明酸、苯二酚及其衍生物等等。但是,上述皮肤美白剂对酪氨酸酶活性的抑制以及在阻断黑色素合成途径的作用不同,效率不一。
全球公认的美白黄金“光甘草定”,目前市场上通常以40%含量的为主要产品,研究表明,提取成本高昂的90%含量以上的光甘草定产品,其美白效率远超过低含量的光甘草定产品,同时光甘草定的不同提取来源,很大程度上也影响着美白效率,光果甘草根部提取的光甘草定被认为是最好的光甘草定。90%含量的光果甘草根提取的光甘草定采用载体技术,可以最大程度发挥其美白亮肤功效,使用载体技术是目前研究光甘草定的最先进的美白技术。
传统的剥落角质层技术是以果酸,水杨酸等为主,其在加速剥落的过程中,带来的如刺激性等负面影响,同样是化妆品配方师难以回避的问题。羟乙基哌嗪乙烷磺酸(HEPES),可以软化角质,非常温和促进肌肤表皮层的老旧角质细胞剥落,可以光滑、柔软肌肤,提亮肤色,达到美白的功效。同时,在活性成分存在的化妆品配方体系中,HEPES可以有效促进皮肤对活性成分的吸收,在不同的化妆品配方中,可以较长时间控制恒定的pH范围,起到保护活性成分,稳定配方体系的作用。另外,因其UVA波段和可见光波段有吸收性,在防晒配方中,可以协同防晒。
内皮素拮抗剂是一类内源性的多肽类物质,由血管内皮细胞产生,包括ET-1,ET-2和ET-3三种多肽。90年代中期皮肤生理学家发现人体皮肤被紫外线(UVB)照射后,角朊细胞释放出内皮素,该内皮素的信息被黑色素细胞膜上的受体接受后,刺激了黑色素细胞的分化、增殖并激活酪氨酸酶的活性,从而黑色素急剧增加。内皮素是造成色斑的主要原因。
天然植物,经过时间和空间的洗礼,生长于各种各样环境的自然界,天然生长环境是其具有了各种抵御外界的能力,植物体内的鲜活成分是其具备抵御外界能力的最重要因素,亮肤和美白功效的鲜活成分成为配方师越来越重要的选择。
上述背景技术[0004]中提及的市场上常用美白剂不能综合考虑皮肤美白的各个环节,例如:从黑色素生成诱因、黑色素生成过程到最后黑色素随角质剥落排出过程等等。
发明内容
本发明的目的在于提供一种美白亮肤的组合物。
本发明的又一目的在于提供这种组合物在化妆品配方中的应用。
一种用于美白亮肤的化妆品组合物,该组合物按质量百分比计包括以下的组分:
作为化妆品配方的优选方案,该组合物按质量百分比计包括以下的组分:
光甘草定载体 2.0-8.0%
羟乙基哌嗪乙烷磺酸(HEPES) 0.2-3.0%。
作为化妆品配方的优选方案,该组合物按质量百分比计包括以下的组分:
光甘草定载体 1.0-5.0%
羟乙基哌嗪乙烷磺酸(HEPES) 0.2-3.0%
内皮素拮抗剂 0.01-2.0%。
作为化妆品配方的优选方案,该组合物按质量百分比计包括以下的组分:
光甘草定载体 1.0-5.0%
羟乙基哌嗪乙烷磺酸(HEPES) 0.2-3.0%
植物复合精华 0.1-5.0%。
以上组合物所述的光甘草定载体来源于光果甘草根提取物,其质量百分含量为1.0-5.0%。
以上组合物所述的光甘草定载体中的光甘草定为质量含量分数大于90%的光甘草定。
以上组合物所述的羟乙基哌嗪乙烷磺酸(HEPES)为粉末物质,其质量纯度大于99%。
以上组合物所述的内皮素拮抗剂是一种水生生物的贝壳硬蛋白经过生物方式得到粉末物质,质量纯度大于75%。
以上组合物所述的植物复合精华,包含:牡丹(PAEONIA SUFFRUTICOSA)枝/花/叶提取物,白花百合(LILIUM CANDIDUM)花提取物,白睡莲(NYMPHAEA ALBA)花提取物,积雪草(CENTELLA ASIATICA)提取物,该植物复合精华是经过高新技术室温提取的植物鲜活成分。
具体实施方式
本发明公开了三种美白亮肤的化妆品配方,这些化妆品配方包括上述的美白亮肤组合物。
本发明提供的美白亮肤的化妆品组合物是以光甘草定载体,羟乙基哌嗪乙烷磺酸(HEPES),内皮素拮抗剂,植物复合精华为主要成分,辅以化妆品常用基质成分乳化剂、润肤剂、保湿剂、增稠剂、防腐剂、香精以及去离子水制成。下面列举部分具体实施案例对本发明进行说明,但不限制本发明的内容。对于未特别注明的工艺参数或条件,可参照常规技术进行。
实施案例1,一种美白亮肤精华,含有如下质量百分含量的各组分:
光甘草定载体5%,羟乙基哌嗪乙烷磺酸(HEPES)2.0%,植物复合精华1%,掌状海带提取物2.0%,青稞多糖(Eamoist HS150P)0.5%,神经酰胺(II)0.5%,EDTA二钠0.05%,尿囊素0.1%,甘油5%,甲基丙二醇1%,卡波姆0.1%,黄原胶0.25%,对羟基苯乙酮0.1%,透明质酸钠0.05%,甘油辛酸酯0.1%,辛酰羟肟酸0.5%,1,2-己二醇0.1%,丙二醇1%,精氨酸0.5%,水余量。
实施案例2,一种美白亮肤精华,含有如下质量百分含量的各组分:
光甘草定载体2%,羟乙基哌嗪乙烷磺酸(HEPES)1.0%,内皮素拮抗剂0.05%,掌状海带提取物2.0%,青稞多糖(Eamoist HS150P)0.5%,神经酰胺(II)0.2%,EDTA二钠0.05%,尿囊素0.1%,甘油5%,甲基丙二醇1%,卡波姆0.1%,黄原胶0.25%,对羟基苯乙酮0.1%,透明质酸钠0.05%,甘油辛酸酯0.1%,1,2-己二醇0.1%,丙二醇1%,水余量。
实施案例3,一种美白亮肤精华,含有如下质量百分含量的各组分:
光甘草定载体2%,羟乙基哌嗪乙烷磺酸(HEPES)1.0%,植物复合精华3%,掌状海带提取物2.0%,青稞多糖(Eamoist HS150P)0.5%,神经酰胺(II)0.2%,EDTA二钠0.05%,尿囊素0.1%,甘油5%,甲基丙二醇1%,卡波姆0.1%,黄原胶0.25%,对羟基苯乙酮0.1%,透明质酸钠0.05%,甘油辛酸酯0.1%,1,2-己二醇0.1%,丙二醇1%,水余量。
美白亮肤效果评价
本实验选择实施案例1中提供的美白亮肤精华进行临床试验。
该试验包括志愿者20人,其中完成试验人数20人。年龄范围25-45岁,其中男性5人,女性15人。志愿者至少在研究开始前7天不得使用任何美白增亮和防晒类化妆产品,以及不要洗太阳浴或使用日光浴床。试验周期为4周,期间每天一次由一位经过培训的技术员执行,涂抹于志愿者的皮肤特定区域,在使用前,及连续使用4周后分别用比色计进行读数,测定L*a*b*值,判定皮肤亮度的变化。
具体测试方法:在每位志愿者的手臂同一位置选取四处为测试区域,每个区域大小为4平方厘米,分别编号为A/B/C区域:A区域为空白(洁净皮肤),B区域使用3.5MED的UVB照射后,立刻测定L*值,并计算出△L(初)数值,在整个测试阶段不作皮肤治疗处理,并测定4周后的L*值,计算△L(终)数值,C区域使用3.5MED的UVB照射后,同时每天一次涂抹本发明的美白亮肤精华产品,并分别测定初始和使用四周后的L*值。其中B区域测定数据的目的是考虑除了涂抹试验样品之外因素(肌肤自我修复能力)而引起的皮肤亮度的变化。
测试数据统计如下:
该测试结果显示志愿者在使用了测试样品后,皮肤平均亮度方面提升非常明显:在经过UVB紫外线照射及4周测试时间后,未使用美白亮肤精华产品的志愿者测试部位,肤色亮度提升19.85%(主要因为在受到UVB紫外线破坏后,皮肤所具有的自我修复能力),但使用了含美白亮肤成分的精华后,4周后志愿者的皮肤亮肤平均提升48.51%。
志愿者感官自我评价:采用问卷调查的形式,由20名志愿者在使用前、使用两周及使用四周后,对自我皮肤白度/亮度的变化来判断产品对美白亮肤的功效情况。
统计数据如下:
使用前,对自我皮肤亮度白度满意的人只占5%;使用2周后,评价有明显改善的人群占70%,评价有改善的人群占25%,评价无改善的占5%;使用4周后评价有明显改善的人群占90%,评价有改善的人群占10%,评价无改善的占0%。
综上所述,该受测试产品,具有明显的美白亮肤的功效。
以上所述的实施案例仅仅是对本发明的优选实施方式进行描述,并非对本发明的范围进行限定,在不脱离本发明设计精神的前提下,本领域普通技术人员对本发明的技术方案作出的各种变形和改进,均应落入本发明权利要求书确定的保护范围内。
Claims (9)
2.根据权利要求1所述的一种用于美白亮肤的化妆品组合物,其特征在于该组合物按质量百分比计包括以下的组分:
光甘草定载体 2.0-8.0%
羟乙基哌嗪乙烷磺酸(HEPES) 0.2-3.0%。
3.根据权利要求1所述的一种用于美白亮肤的化妆品组合物,其特征在于该组合物按质量百分比计包括以下的组分:
光甘草定载体 1.0-5.0%
羟乙基哌嗪乙烷磺酸(HEPES) 0.2-3.0%
内皮素拮抗剂 0.01-2.0%。
4.根据权利要求1所述的一种用于美白亮肤的化妆品组合物,其特征在于该组合物按质量百分比计包括以下的组分:
光甘草定载体 1.0-5.0%
羟乙基哌嗪乙烷磺酸(HEPES) 0.2-3.0%
植物复合精华 0.1-5.0%。
5.根据权利要求1或2或3或4所述的一种美白亮肤的组合物,其特征在于所述的光甘草定载体来源于光果甘草根提取物,其质量百分含量为1.0-5.0%。
6.根据权利要求1或2或3或4所述的一种美白亮肤的组合物,其特征在于所述的光甘草定载体中的光甘草定为质量含量分数大于90%的光甘草定。
7.根据权利要求1或3所述的一种美白亮肤的组合物,其特征在于所述的内皮素拮抗剂是一种水生生物的贝壳硬蛋白经过生物方式得到粉末物质,质量纯度大于75%。
8.根据权利要求1或4所述的一种美白亮肤的组合物,其特征在于所述的植物复合精华,包含:牡丹(PAEONIA SUFFRUTICOSA)枝/花/叶提取物,白花百合(LILIUM CANDIDUM)花提取物,白睡莲(NYMPHAEA ALBA)花提取物,积雪草(CENTELLA ASIATICA)提取物,该植物复合精华是经过高新技术室温提取的植物鲜活成分。
9.一种用于美白亮肤的化妆品,其特征在于该化妆品包括权利要求1-8任意一项权利要求所述的化妆品组合物,以及化妆品各种外用剂型包括但不仅限于膏霜、乳液、面膜、水剂、粉底等。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910001955.1A CN111388382A (zh) | 2019-01-02 | 2019-01-02 | 一种用于美白亮肤的组合物及其在化妆品中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910001955.1A CN111388382A (zh) | 2019-01-02 | 2019-01-02 | 一种用于美白亮肤的组合物及其在化妆品中的应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111388382A true CN111388382A (zh) | 2020-07-10 |
Family
ID=71410726
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910001955.1A Pending CN111388382A (zh) | 2019-01-02 | 2019-01-02 | 一种用于美白亮肤的组合物及其在化妆品中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111388382A (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112315890A (zh) * | 2020-11-24 | 2021-02-05 | 北京鸣聚力商贸有限责任公司 | 一种美白亮肤组合物及其制备方法和应用 |
CN113908073A (zh) * | 2021-11-18 | 2022-01-11 | 广州梵之容化妆品有限公司 | 一种美白水及其制备方法 |
CN114588068A (zh) * | 2022-03-29 | 2022-06-07 | 上海新高姿化妆品有限公司 | 具有皮肤美白淡斑功效的组合物 |
CN114732752A (zh) * | 2022-03-17 | 2022-07-12 | 欧诗漫生物股份有限公司 | 用于皮肤美白的组合物及其用途 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20070052211A (ko) * | 2005-11-16 | 2007-05-21 | 주식회사 엠디바이오알파 | 글라브리딘을 유효성분으로 함유하는 질환 증후군 예방 및치료용 조성물 |
CN104688652A (zh) * | 2015-03-17 | 2015-06-10 | 欧诗漫生物股份有限公司 | 一种用于美白皮肤的化妆品组合物及其制备方法 |
CN107224412A (zh) * | 2016-03-23 | 2017-10-03 | 欧诗漫生物股份有限公司 | 一种化妆品美白乳液及其制备方法 |
CN108066218A (zh) * | 2017-12-28 | 2018-05-25 | 广州蜜妆生物科技有限公司 | 一种美白亮肤的组合物 |
CN108815037A (zh) * | 2018-08-02 | 2018-11-16 | 广州航美化妆品有限公司 | 一种美白焕颜护肤组合物及其在化妆品中的应用 |
-
2019
- 2019-01-02 CN CN201910001955.1A patent/CN111388382A/zh active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20070052211A (ko) * | 2005-11-16 | 2007-05-21 | 주식회사 엠디바이오알파 | 글라브리딘을 유효성분으로 함유하는 질환 증후군 예방 및치료용 조성물 |
CN104688652A (zh) * | 2015-03-17 | 2015-06-10 | 欧诗漫生物股份有限公司 | 一种用于美白皮肤的化妆品组合物及其制备方法 |
CN107224412A (zh) * | 2016-03-23 | 2017-10-03 | 欧诗漫生物股份有限公司 | 一种化妆品美白乳液及其制备方法 |
CN108066218A (zh) * | 2017-12-28 | 2018-05-25 | 广州蜜妆生物科技有限公司 | 一种美白亮肤的组合物 |
CN108815037A (zh) * | 2018-08-02 | 2018-11-16 | 广州航美化妆品有限公司 | 一种美白焕颜护肤组合物及其在化妆品中的应用 |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112315890A (zh) * | 2020-11-24 | 2021-02-05 | 北京鸣聚力商贸有限责任公司 | 一种美白亮肤组合物及其制备方法和应用 |
CN113908073A (zh) * | 2021-11-18 | 2022-01-11 | 广州梵之容化妆品有限公司 | 一种美白水及其制备方法 |
CN114732752A (zh) * | 2022-03-17 | 2022-07-12 | 欧诗漫生物股份有限公司 | 用于皮肤美白的组合物及其用途 |
CN114732752B (zh) * | 2022-03-17 | 2023-10-13 | 欧诗漫生物股份有限公司 | 用于皮肤美白的组合物及其用途 |
CN114588068A (zh) * | 2022-03-29 | 2022-06-07 | 上海新高姿化妆品有限公司 | 具有皮肤美白淡斑功效的组合物 |
CN114588068B (zh) * | 2022-03-29 | 2023-07-28 | 上海新高姿化妆品有限公司 | 具有皮肤美白淡斑功效的组合物 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101884411B1 (ko) | 미백 및 보습용 기능성 화장료 조성물 | |
KR102044562B1 (ko) | 화장 조성물 | |
CN111388382A (zh) | 一种用于美白亮肤的组合物及其在化妆品中的应用 | |
US7429391B2 (en) | Holistic composition and method for reducing skin pigmentation | |
KR101438367B1 (ko) | 인삼 열매 추출물을 함유하는 피부 외용제 조성물 | |
US20030157202A1 (en) | Lightening compositions and methods of use | |
EP2968107B1 (en) | Cosmetic compositions and uses thereof | |
ES2638976T3 (es) | Composición cosmética que contiene producto de baya de ginseng con Pleurotus ferulae fermentado | |
CN110623882A (zh) | 一种美白祛斑面膜及其制备方法 | |
CN114681358B (zh) | 一种酪氨酸酶活性抑制剂及具有增效美白作用的护肤品 | |
KR101928797B1 (ko) | 컴파운드 k를 함유하는 피부 외용제 조성물 | |
CN107456415B (zh) | 一种美白增亮组合物 | |
CN113797114A (zh) | 局部用组合物和方法 | |
KR20140066521A (ko) | 점액을 분비하는 어류로부터 수득한 점액을 함유하는 화장료 조성물 | |
KR101131574B1 (ko) | 피부 미백용 조성물 | |
CN108524354A (zh) | 护肤组合物、护肤面膜及其制备方法 | |
Murphy et al. | Clinical studies of the safety and efficacy of macroalgae extracts in cosmeceuticals | |
KR102373899B1 (ko) | 피부의 주름 개선, 미백, 세포 재생, 상처 치유에 유효한 복합 천연물 추출물을 활성성분으로 함유하는 다 기능성 화장품 조성물 | |
KR101939112B1 (ko) | 진세노사이드 f1을 함유하는 피부 외용제 조성물 | |
KR101934793B1 (ko) | 고욤나무 잎 추출물을 유효성분으로 함유하는 피부 광노화 예방 또는 개선용 조성물 | |
KR100678864B1 (ko) | 천궁 추출물 및 카르니틴을 유효성분으로 함유하는 피부미백용 화장료 조성물 | |
KR100887631B1 (ko) | 인삼 열매 추출물을 함유하는 피부 외용제 조성물 | |
CN109363956B (zh) | 喜来芝提取物的用途和美白水分露及其制备方法 | |
CN104470488A (zh) | Dickkopf-1表达调节组合物及其用途 | |
KR101909533B1 (ko) | 진세노사이드 f1을 함유하는 피부 외용제 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200710 |